Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway
Figure 3
Proportion of explained uncertainty in model outcomes (incremental QALYs, costs, and net-monetary benefit at WTP of 400,000 NOK) by the most relevant variables for the comparison of etoricoxib (90 mg) versus celecoxib, diclofenac, and naproxen (base-case scenario).
